Doxycycline containing hydroxyapatite ceramic microspheres as a bone‐targeting drug delivery system. Issue 4 (8th September 2019)

• Record Type: Journal Article
• Authors: Soriano‐Souza, Carlos; Valiense, Helder; Mavropoulos, Elena; Martinez‐Zelaya, Victor; Costa, Andrea Machado; Alves, Adriana T.; Longuinho, Mariana; Resende, Rodrigo; Mourão, Carlos; Granjeiro, Jose; Rocha‐Leao, Maria H.; Rossi, Alexandre; Calasans‐Maia, Mônica
• Is Part Of: Journal of biomedical materials research. Volume 108:Issue 4(2020)
• Page Start: 1351
• Page End: 1362
• Publication Date: 2019-09-08
• Subjects: biocompatibility -- cytotoxicity -- doxycycline -- drug delivery -- hydroxyapatite; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.b.34484
• Languages: English
• ISSNs: 1552-4973

Abstract

Abstract: Drug delivery technology is a promising way to enhance the therapeutic efficacy of drugs. The purpose of this study is to evaluate the physical and chemical properties of hydroxyapatite ceramic microspheres loaded with doxycycline (HADOX), their effects on in vitro osteoblast viability, and their antimicrobial activity, and to determine the effects of DOX on the healing of rat sockets after tooth extraction. The internal microsphere porosity was sensitive to the treatment used to adsorb DOX onto microsphere surface; HA microspheres without DOX presented 26% of pores, whereas HADOX0.15 microspheres presented 52.0%. An initial drug release of 49.15 μg/ml was observed in the first 24 hr. The minimal inhibitory concentration (MIC) tested against Enterococcus faecalis demonstrated that bacterial growth was inhibited for up to 7 days. Results of cell viability and cell proliferation did not indicate statistical differences in the metabolic activity of HADOX samples relative to HA without DOX microspheres ( p > .05). After 1 week, a discreet inflammation reaction was observed in the control group, and after 6 weeks, newly‐formed bone was observed in the HADOX0.15 ( p < .05). The HADOX did not interfere in the bone repair and controlled the early inflammatory response. HADOX could be a promising biomaterial to promote bone repair in infected sites.